# A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)

Source: https://onco.cc/trials/nct05094336/  
OnCo record `nct05094336` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Anvumetostat and Docetaxel in advanced solid tumours, run by Amgen, active and no longer recruiting.

## Summary

A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) is a phase 1/2 interventional study registered as NCT05094336 by Amgen, with 329 participants enrolled, started 2022-02-01 and due to reach its primary completion in 2026-11-30. Interventions recorded: Anvumetostat, Docetaxel and Comparator Anvumetostat Test Tablet.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05094336
- Phase: 1/2
- Setting: A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Anvumetostat Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors
- Sponsor: Amgen
- Enrolled: 329

## Sources

- ClinicalTrials.gov NCT05094336: https://clinicaltrials.gov/study/NCT05094336

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Anvumetostat](https://onco.cc/drugs/anvumetostat/), [Docetaxel](https://onco.cc/drugs/docetaxel/)
- companies: [Amgen](https://onco.cc/companies/amgen/)

---
JSON: https://onco.cc/api/v1/entities/nct05094336.json